Multiple sclerosis

1 Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis
X Montalvan, D Wallace, M C Genovese, D Tomic, D Parsons-Rich, C Le Bolay, A H Kao, G Guebing

10 Spinal cord lesions and brain grey matter atrophy independently predict clinical worsening in definite multiple sclerosis: a 5-year, multicentre study

19 Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations

23 Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network

31 Brain age gap in neuromyelitis optica spectrum disorders and multiple sclerosis
R Wei, X Xu, Y Duan, N Zhang, J Sun, H Li, Y Li, Y Li, C Zeng, X Han, F Zhou, M Huang, R Li, Z Zhuo, F Barkhof, J H Cole, Y Liu

38 Safety of breast feeding during rituximab treatment in multiple sclerosis
B E Red, O Torkildsen, K-M Myhr, I Be, S Wergeland

42 Levetiracetam versus fosphenytoin as a second-line treatment after diazepam for adult convulsive status epilepticus: a multicentre non-inferiority randomised control trial
K Nakamura, A Marashima, Y Takahashi, M Mochizuki, A Kimura, Y Poluda, M Asami, H Nakamoto, S Egawa, J Kaneko, K Unemoto, Y Kondo, C Yonekawa, M Uchida, E Hoshiyama, T Yamada, K Maruo, E Ishikawa, Y Matsunaru, Y Inoue, JNEC ECT with the LIFE study group

49 Short-lasting unilateral neuralgiform headache attacks (SUNCT/SUNA): a narrative review of interventional therapies
R D Oma, N Mousheidan, K C Kang, M Reyes, A Sathe, S Collopy, G Peashant, H Yuan, J Evans

Disclaimer: The Editor of JNNP has been granted editorial freedom and JNNP is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. JNNP is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by JNNP does not imply endorsement. BMJ Publishing Group Limited shall not be liable for any loss, injury or damage however arising from JNNP (except for liability which cannot be legally excluded).

Copyright: © 2023 BMJ Publishing Group Ltd. All rights reserved; no part of this publication may be reproduced in any form without permission.

JNNP is published by BMJ Publishing Group Ltd, 11413, USA Postmark address to Journal of Neurology Neurosurgery & Psychiatry, World Container Inc, 150-15, 18th Street, Jamaica, NY 11433, USA. Subscription records are maintained at BMJ House, Tavistock Square, WC1H 9JR London Air Business Ltd is acting as our mailing agent.
Neuro-inflammation

57  Association of obesity with disease outcome in multiple sclerosis

62  Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis
G Spagni, B Sun, G Monte, E Sechi, R Ionó, A Evoli, V Damato

Cerebrovascular disease

70  Circadian rhythm of ischaemic core progression in human stroke
P Radler, A Brehm, P B Sporns, V G Barbara, L Stueckelschweiger, G Broocks, T Lüdtge, M-N Psychogios, J Riecke, K Dimitriadis, M Dichtlans, W G Kurtz, S Tiedt

74  High frequency of HTRA1 AND ABCC6 mutations in Japanese patients with adult-onset cerebral small vessel disease

Neurodegeneration

83  Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer’s disease
L Barba, S Abu Rumeileh, G Bellomo, F Paolini Paolenti, S Haldighihauser, P Oeckl, P Steinacker, F Massa, L Gaetani, L Parretti, M Otto

PostScript

87  Letters